CTOs on the Move

Zimmer Holdings, Inc.

www.zimmer.com

 
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer`s 2009 sales were approximately $4.1 billion. The Company is supported by the efforts of approximately 8,500 employees worldwide.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.zimmer.com
  • 345 East Main Street P.O. Box 708,
    Warsaw, IN USA 46580
  • Phone: 574.267.6131

Executives

Name Title Contact Details

Similar Companies

Poudre Valley Health System

Poudre Valley Health System is a Fort Collins, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Global Widget

We’re creative and passionate professionals on a mission – to deliver top-notch natural health products to a global community. 🍃💪

Story County Medical Center

Story County Medical Center is full-service, primary-care medical center dedicated to providing you high quality healthcare in a community-oriented manner. We value personal service, open communications, a team approach to your care and the relationships built along the way.

Innerpulse

Innerpulse is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.